Eli Lilly announced new clinical data presentations at the 2026 European Society for Medical Oncology (ESMO) Congress, featuring updates on several investigational and approved cancer therapies. Key highlights include Phase 1 data for sofetabart mipitecan combined with bevacizumab in platinum-sensitive ovarian cancer, updated first-line data for olomorasib in KRAS G12C-mutant lung cancer, Phase 3 results for selpercatinib in RET-mutant thyroid cancer, and overall survival data for abemaciclib in advanced breast cancer. These findings support ongoing Phase 3 trials and reinforce Lilly's commitment to advancing targeted cancer treatments. The presentations mark significant progress toward improving outcomes across multiple cancer types.
Eli Lilly And Co (LLY) trades at USD 1,257.03 on Pluang as of Oct 19, 2026 05:21 WIB, showing a modest 0.43% increase in the past day. The company holds a substantial market cap of $1.12 trillion and an enterprise value of $1.17 trillion, reflecting its significant presence in the health sector. These figures highlight investor confidence as Lilly prepares to showcase advances in its oncology pipeline at the upcoming 2026 ESMO Congress.
Eli Lilly transformed from a traditional insulin maker into a pharmaceutical giant, driven by its obesity drug Tirzepatide, sold as Mounjaro and Zepbound. These drugs generated $14.9 billion in Q2 2026 alone, capturing 60% of U.S. obesity prescriptio...
The obesity treatment landscape is rapidly evolving with over 200 companies developing more than 200 pipeline drugs, including late-stage and early-stage clinical trials. Major pharmaceutical firms like Novo Nordisk and Eli Lilly are leading with inn...
Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026, followed by a conference call at 10 a.m. Eastern time to discuss the company's performance. The call will be accessible via a live webcast on Lilly's investor websi...
New data from Eli Lilly reveal that Omvoh (mirikizumab-mrkz) effectively achieves comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease after one year of treatment. These outcomes, observed even...
